Summary
GHRP-2 is a hexapeptide ghrelin-receptor agonist and one of the most potent GH releasers in its class. As pralmorelin, it is used in Japan as a diagnostic test for growth hormone deficiency. It raises cortisol and prolactin more than ipamorelin.
Structure
D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys-NH2.
How it works
Activates GHS-R1a and acts synergistically with GHRH. In diagnostic use, a single dose provokes GH release so clinicians can assess pituitary reserve.
Research use cases
Areas where GHRP-2 has been studied. Inclusion here does not mean it works for that purpose.
- Diagnostic testing for GH deficiency (Japan)
- GH secretion physiology
What the research found
Class pharmacology
GHRP-2 belongs to the hexapeptide family first characterized by Bowers. Combined GHRP and GHRH stimulation produces synergistic GH release, which underlies its diagnostic use.1
Safety and open questions
Raised cortisol and prolactin, increased appetite and flushing. Detected in anti-doping testing.
Regulatory status
Approved in Japan (as pralmorelin) as a diagnostic agent for GH deficiency. Not approved in the US. Prohibited by WADA. Remains in FDA compounding Category 2.
Status was accurate when this page was last reviewed on October 26, 2026. Regulations change; check with the relevant authority before relying on it.
GHRP-2: common questions
Is GHRP-2 stronger than GHRP-6?
In most comparisons, GHRP-2 releases more GH per dose and causes less hunger than GHRP-6, but more cortisol and prolactin than ipamorelin.
Is GHRP-2 approved for human use?
Approved in Japan (as pralmorelin) as a diagnostic agent for GH deficiency. Not approved in the US. Prohibited by WADA. Remains in FDA compounding Category 2.
References
- Bowers CY, Momany FA, Reynolds GA, Hong A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology.
Links open a PubMed search for the exact title, or the original source where one is given.